Journal
NATURAL PRODUCT RESEARCH
Volume 36, Issue 10, Pages 2580-2584Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14786419.2021.1904923
Keywords
Chlorogenic acid; COVID-19; mechanism; network pharmacology; molecular docking
Categories
Funding
- National Natural Science Foundation [81903922, 81973573, 81973569]
- National Key Research and Development Program of China [2017YFC1703904]
- Project First-Class Disciplines Development of Chengdu University of Traditional Chinese Medicine [CZYJC1903]
- Xinglin Scholar Research Premotion Project of Chengdu University of TCM [CXTD2018015, CXTD2018020]
Ask authors/readers for more resources
Chlorogenic acid (CGA) is a potential inhibitor of COVID-19, affecting multiple potential targets and demonstrating anti-SARS-CoV-2 activity.
Chlorogenic acid (CGA) is a potential inhibitor of Coronavirus Disease 2019 (COVID-19). ACE2 and its co-expressed proteins are SARS-CoV-2 receptors, which have been linked to SARS-CoV-2 infection and considered as the key target of SARS-CoV-2 in entering target cells. Here, network pharmacology was used to investigate the mechanism by which CGA affected COVID-19. A total of 70 potential targets related to the treatment of COVID-19 were obtained, among which NFE2L2, PPARG, ESR1, ACE, IL6, and HMOX1 might be the main potential targets. Finally, CGA and potential target proteins were scored by molecular docking, and the prediction results of network pharmacology were preliminarily verified. Moreover, CGA had potential anti-SARS-CoV-2 activity via integrating three common receptors in clinical practice compared with clinical trial drugs registered for the treatment of COVID-19, as shown by molecular docking. The mechanism of CGA against COVID-19 was initially investigated using network pharmacology, followed by molecular docking.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available